Clinical trial
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of…
NCT00392821 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00392821 |
|---|---|
| Title | Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer |
| Official title | Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Novartis Industry Bayer |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib, RAD001 |
| Enrollment | 78 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2013 |
| Completion | Oct 1, 2013 |
| First posted | Oct 26, 2006 |
| Last update posted | Jun 6, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: